Hovione has purchased 75% of Hisyn Pharmaceutical Co. Ltd. The acquisition “provides Hovione with significant drug substance manufacturing production capacity and strengthens its 20-year presence in China,” according to a company statement. The acquisition includes both development labs in Shanghai and an active pharmaceutical ingredient (API) plant occupying 22,000 square meters on a 22-acre plot employing 181 staff. Hovione’s relationship with Hisyn started with the supply of...